Tech Company Financing Transactions
Northwest Biotherapeutics Funding Round
Northwest Biotherapeutics closed a $15 million funding round on 11/30/2021. Investors included private investors.
Transaction Overview
Company Name
Announced On
11/30/2021
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The Company plans to use the funding to help accelerate its activities related to its brain cancer program.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4800 Montgomery Ln. 800
Bethesda, MD 20814
USA
Bethesda, MD 20814
USA
Phone
Website
Email Address
Overview
Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax, uses a patient's own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Linda Powers
Chief Scientific Officer
Alton Boynton
Chief Technical Officer
Marnix Bosch
VP - Bus. Development
Les Goldman
Browse more venture capital transactions:
Prev: 11/30/2021: Particular Audience venture capital transaction
Next: 11/30/2021: Armis venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs